Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Andrew's Options

<< Previous

Bullboard Posts

Next >>

Comment by 2O2Ovisionon Nov 17, 2023 2:01pm

145 Views

Post# 35741569

RE:RE:RE:Andrew's Options

Simply think it's because they're expiring shortly and one can assume he didn't think the 1.45 could be beat on the open market. Either way it helps the optics. Anyone can check out the report for the others who all have options expring before year end. This board doesn't always allows copy and paste in a readable format so my appologies.

Andrew de Guttadauro options / price / expiry at the end of 2022 (see FY report p.47)
13,157 4.94 7/3/2027
30,000 2.73 12/14/2023
100,000 1.45 12/13/2023
200,000 3.17 12/11/2024
85,000 3.40 3/8/2026
55,000 2.08 12/10/2025
80,000 2.31 12/9/2026

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024